| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mayela Rodríguez-Violante, Ana J Hernández-Medrano, Amin Cervantes-Arriaga, Cesarina Torres-Vásquez, Dioselina Tristán-Samaniego, Carolina Zepeda-Salazar, Victoria Cerino-Palomino, Arturo Abundes-Coron. Levodopa versus levodopa sparing in early parkinson's disease: can we meet halfway? Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion. vol 76. issue 3. 2024-07-19. PMID:39028854. |
early evidence on the potential role of levodopa formulations in the risk of dyskinesia led to levodopa aversion in the late 1990s and early 2000s, favoring the use of levodopa-sparing options like dopamine agonists. |
2024-07-19 |
2024-07-22 |
Not clear |
| Pengfei Wang, Yuewei Bi, Min Li, Jiazhi Chen, Zhuyong Wang, Huantao Wen, Ming Zhou, Minjie Luo, Wangming Zhan. Cortico-striatal gamma oscillations are modulated by dopamine D3 receptors in dyskinetic rats. Neural regeneration research. vol 20. issue 4. 2024-07-11. PMID:38989954. |
administration of pd128907 (a selective dopamine d3 receptor agonist) induced dyskinesia and excessive gamma oscillations with a bidirectional m1 ↔ dorsolateral striatum flow. |
2024-07-11 |
2024-07-13 |
rat |
| Pengfei Wang, Yuewei Bi, Min Li, Jiazhi Chen, Zhuyong Wang, Huantao Wen, Ming Zhou, Minjie Luo, Wangming Zhan. Cortico-striatal gamma oscillations are modulated by dopamine D3 receptors in dyskinetic rats. Neural regeneration research. vol 20. issue 4. 2024-07-11. PMID:38989954. |
these findings suggest that the dopamine d3 receptor plays a role in dyskinesia-related oscillatory activity, and that it has potential as a therapeutic target for levodopa-induced dyskinesia. |
2024-07-11 |
2024-07-13 |
rat |
| Yuan-Hao Chen, Tung-Tai Kuo, Vicki Wang, Pin-Wen Cheng, Eagle Yi-Kung Huang, Kuo-Hsing Ma, Nigel H Greig, Lars Olson, Barry J Hoffer, Kuan-Yin Tsen. Serotonergic Regulation of Synaptic Dopamine Levels Mitigates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease. Journal of Parkinson's disease. 2024-06-21. PMID:38905058. |
serotonergic regulation of synaptic dopamine levels mitigates l-dopa-induced dyskinesia in a mouse model of parkinson's disease. |
2024-06-21 |
2024-06-24 |
mouse |
| Demetra Ballardin, Leila Makrini-Maleville, Alexander Seper, Emmanuel Valjent, Heike Rebhol. 5-HT4R agonism reduces L-DOPA-induced dyskinesia via striatopallidal neurons in unilaterally 6-OHDA lesioned mice. Neurobiology of disease. 2024-06-09. PMID:38852753. |
in parkinson's disease therapy, dopamine loss is counteracted by the administration of l-dopa, which is initially effective in ameliorating motor symptoms, but over time leads to a burdening side effect of uncontrollable jerky movements, termed l-dopa-induced dyskinesia. |
2024-06-09 |
2024-06-14 |
mouse |
| Santiago Uribe-Cano, Lauren Malave, Andreas H Kottman. L-Dopa induced dyskinesias require Cholinergic Interneuron expression of Dopamine 2 receptor. bioRxiv : the preprint server for biology. 2024-05-20. PMID:38765986. |
l-dopa induced dyskinesias require cholinergic interneuron expression of dopamine 2 receptor. |
2024-05-20 |
2024-05-27 |
Not clear |
| David A Figge, Henrique de Amaral Oliveira, Jack Crim, Rita M Cowell, David G Standaert, Karen L Eskow Jaunaraj. Differential activation states of direct pathway striatal output neurons during L-DOPA-induced dyskinesia development. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2024-04-25. PMID:38664012. |
l-dopa-induced dyskinesia (lid) is a debilitating motor side effect arising from chronic dopamine (da) replacement therapy with l-dopa for the treatment of parkinson disease. |
2024-04-25 |
2024-04-28 |
mouse |
| Jeongrak Park, Seongtak Kang, Yaebin Lee, Ji-Woong Choi, Yong-Seok O. Continuous long-range measurement of tonic dopamine with advanced FSCV for pharmacodynamic analysis of levodopa-induced dyskinesia in Parkinson's disease. Frontiers in bioengineering and biotechnology. vol 12. 2024-02-08. PMID:38328444. |
continuous long-range measurement of tonic dopamine with advanced fscv for pharmacodynamic analysis of levodopa-induced dyskinesia in parkinson's disease. |
2024-02-08 |
2024-02-10 |
Not clear |
| Jeongrak Park, Seongtak Kang, Yaebin Lee, Ji-Woong Choi, Yong-Seok O. Continuous long-range measurement of tonic dopamine with advanced FSCV for pharmacodynamic analysis of levodopa-induced dyskinesia in Parkinson's disease. Frontiers in bioengineering and biotechnology. vol 12. 2024-02-08. PMID:38328444. |
levodopa, a dopamine prodrug, alleviates the motor symptoms of parkinson's disease (pd), but its chronic use gives rise to levodopa-induced dyskinesia (lid). |
2024-02-08 |
2024-02-10 |
Not clear |
| Dongxue Zhu, Shenyang Zhang, Xiaoying Wang, Chenghua Xiao, Guiyun Cui, Xinxin Yan. Secretory Clusterin Inhibits Dopamine Neuron Apoptosis in MPTP Mice by Preserving Autophagy Activity. Neuroscience. 2024-01-19. PMID:38242280. |
these results indicated that sclu intervention could reduce the loss of dopamine neurons in the sn area and alleviate dyskinesia in mice. |
2024-01-19 |
2024-01-22 |
mouse |
| Denisson Augusto Bastos Leal, Carla Michele Vieira Dias, Rodrigo Pereira Ramos, Ivani Bry. Prediction of dyskinesia in Parkinson's disease patients using machine learning algorithms. Scientific reports. vol 13. issue 1. 2023-12-19. PMID:38104147. |
dyskinesias are non preventable abnormal involuntary movements that represent the main challenge of the long term treatment of parkinson's disease (pd) with the gold standard dopamine precursor levodopa. |
2023-12-19 |
2023-12-21 |
Not clear |
| Vladimir M Pogorelov, Michael L Martini, Jian Jin, William C Wetsel, Marc G Caro. Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists. Biomolecules. vol 13. issue 11. 2023-11-25. PMID:38002340. |
dopamine-depleted dopamine transporter knockout (ddd) mice: dyskinesia with l-dopa and dopamine d1 agonists. |
2023-11-25 |
2023-11-28 |
mouse |
| Z Pirtošek, V Leta, P Jenner, M Véri. Should continuous dopaminergic stimulation be a standard of care in advanced Parkinson's disease? Journal of neural transmission (Vienna, Austria : 1996). 2023-11-06. PMID:37930456. |
these therapies seek to provide continuous stimulation of striatal dopamine receptors that is efficient not only in alleviating clinical symptoms, but also in delaying, reducing, and possibly preventing the onset of levodopa-related motor (fluctuations, dyskinesia) and non-motor complications; and they are also associated with clinically relevant side effects. |
2023-11-06 |
2023-11-08 |
Not clear |
| Iman Touati, Mohnad Abdalla, Yassir Boulaamane, Nawal Al-Hoshani, Abdulaziz Alouffi, Mohammed Reda Britel, Amal Maurad. Identification of novel dual acting ligands targeting the adenosine A2A and serotonin 5-HT1A receptors. Journal of biomolecular structure & dynamics. 2023-10-18. PMID:37850444. |
pd is the second most ubiquitous neurological disorder after alzheimer's disease, characterized by the depletion of dopamine in the central nervous system due to the impairment of dopaminergic neurons, leading to involuntary movements or dyskinesia. |
2023-10-18 |
2023-11-08 |
Not clear |
| Mariah J Lelos, Ellen M Murphy, Hanna S Lindgren, Stephen B Dunnett, Emma L Lan. Impaired cognitive and motor function are coincident with L-DOPA-induced dyskinesia in a model of Parkinson's disease. Scientific reports. vol 13. issue 1. 2023-10-17. PMID:37848479. |
in parkinson's disease (pd), dopamine replacement using the precursor drug l-dopa is the predominant treatment approach, but long-term exposure leads to the onset of dyskinesias (lids). |
2023-10-17 |
2023-11-08 |
Not clear |
| Andrew J Flores, Mitchell J Bartlett, Blake T Seaton, Grace Samtani, Morgan R Sexauer, Nathan C Weintraub, James R Siegenthaler, Dong Lu, Michael L Heien, Frank Porreca, Scott J Sherman, Torsten Fal. Antagonism of kappa opioid receptors accelerates the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion. Brain research. 2023-10-02. PMID:37783263. |
antagonism of kappa opioid receptors accelerates the development of l-dopa-induced dyskinesia in a preclinical model of moderate dopamine depletion. |
2023-10-02 |
2023-10-07 |
rat |
| Yoshifumi Abe, Sho Yagishita, Hiromi Sano, Yuki Sugiura, Masanori Dantsuji, Toru Suzuki, Ayako Mochizuki, Daisuke Yoshimaru, Junichi Hata, Mami Matsumoto, Shu Taira, Hiroyoshi Takeuchi, Hideyuki Okano, Nobuhiko Ohno, Makoto Suematsu, Tomio Inoue, Atsushi Nambu, Masahiko Watanabe, Kenji F Tanak. Shared GABA transmission pathology in dopamine agonist- and antagonist-induced dyskinesia. Cell reports. Medicine. 2023-09-29. PMID:37774703. |
shared gaba transmission pathology in dopamine agonist- and antagonist-induced dyskinesia. |
2023-09-29 |
2023-10-07 |
mouse |
| Yoshifumi Abe, Sho Yagishita, Hiromi Sano, Yuki Sugiura, Masanori Dantsuji, Toru Suzuki, Ayako Mochizuki, Daisuke Yoshimaru, Junichi Hata, Mami Matsumoto, Shu Taira, Hiroyoshi Takeuchi, Hideyuki Okano, Nobuhiko Ohno, Makoto Suematsu, Tomio Inoue, Atsushi Nambu, Masahiko Watanabe, Kenji F Tanak. Shared GABA transmission pathology in dopamine agonist- and antagonist-induced dyskinesia. Cell reports. Medicine. 2023-09-29. PMID:37774703. |
dyskinesia is involuntary movement caused by long-term medication with dopamine-related agents: the dopamine agonist 3,4-dihydroxy-l-phenylalanine (l-dopa) to treat parkinson's disease (l-dopa-induced dyskinesia [lid]) or dopamine antagonists to treat schizophrenia (tardive dyskinesia [td]). |
2023-09-29 |
2023-10-07 |
mouse |
| Yoshifumi Abe, Sho Yagishita, Hiromi Sano, Yuki Sugiura, Masanori Dantsuji, Toru Suzuki, Ayako Mochizuki, Daisuke Yoshimaru, Junichi Hata, Mami Matsumoto, Shu Taira, Hiroyoshi Takeuchi, Hideyuki Okano, Nobuhiko Ohno, Makoto Suematsu, Tomio Inoue, Atsushi Nambu, Masahiko Watanabe, Kenji F Tanak. Shared GABA transmission pathology in dopamine agonist- and antagonist-induced dyskinesia. Cell reports. Medicine. 2023-09-29. PMID:37774703. |
our findings indicate that lowered type 2 dopamine receptor signaling with repetitive dopamine fluctuations is a common cause of vgat overexpression and late-onset dyskinesia formation and that reducing dopamine fluctuation rescues dyskinesia pathology via vgat downregulation. |
2023-09-29 |
2023-10-07 |
mouse |
| María Sáez, Ettel Keifman, Samuel Alberquilla, Camila Coll, Ramón Reig, Mario Gustavo Murer, Rosario Moratall. D2 dopamine receptors and the striatopallidal pathway modulate L-DOPA-induced dyskinesia in the mouse. Neurobiology of disease. 2023-09-08. PMID:37683958. |
d2 dopamine receptors and the striatopallidal pathway modulate l-dopa-induced dyskinesia in the mouse. |
2023-09-08 |
2023-10-07 |
mouse |